Literature DB >> 24680312

Trochleoplasty versus nontrochleoplasty procedures in treating patellar instability caused by severe trochlear dysplasia.

Guan-Yang Song1, Lei Hong1, Hui Zhang1, Jin Zhang1, Xu Li1, Yue Li1, Hua Feng2.   

Abstract

PURPOSE: The purpose of this study was to compare the clinical outcomes and postoperative complication rates between patients who underwent trochleoplasty or nontrochleoplasty procedures in treating patellar instability caused by severe trochlear dysplasia (STD).
METHODS: The PubMed database was searched using specific inclusion and exclusion criteria for clinical studies reporting indexed orthopaedic treatments of patellar instability caused by STD (Dejour type B to D). Participants within studies were classified into one of the 2 treatment groups: (1) the trochleoplasty group (group T) and (2) the nontrochleoplasty group (group N). Clinical outcomes and postoperative complications were analyzed.
RESULTS: Seventeen studies were finally included. There were in total 459 knees that underwent the indexed orthopaedic treatments of patellar instability caused by STD (Dejour type B to D). Eleven studies, including 329 knees, formed the trochleoplasty group (group T), and the remaining 6 studies, including 130 knees, composed the nontrochleoplasty group (group N). All the clinical outcomes within groups had improved significantly (P < .05) at the final follow-up. No studies directly compared the clinical outcomes between the 2 groups. The postoperative complication analysis showed superior results for the trochleoplasty group in (1) patellar redislocation rate and (2) percentage of patellofemoral osteoarthritis (Iwano grade 2 or greater) progression findings but an inferior outcome with respect to the range of motion (ROM) deficit compared with the nontrochleoplasty group.
CONCLUSIONS: This systematic review showed significant postoperative improvements both in patients undergoing the trochleoplasty procedures and in patients undergoing the nontrochleoplasty procedures for the treatment of patellar instability caused by STD in all the included studies. However, there is limited evidence regarding the comparative advantages toward the optimal treatment. The postoperative complication rate has been considered to be the best measurement of operative success. To prevent the patella from redislocating and patellofemoral osteoarthritis from progressing, trochleoplasty procedures should be considered. Meanwhile, one should be cautious about the postoperative ROM deficit before choosing trochleoplasty procedures. LEVEL OF EVIDENCE: Level IV, systematic review of Level III and IV studies.
Copyright © 2014 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24680312     DOI: 10.1016/j.arthro.2014.01.011

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  14 in total

1.  Double-bundle anatomical medial patellofemoral ligament reconstruction with lateral retinaculum plasty can lead to good outcomes in patients with patellar dislocation.

Authors:  Yingzhen Niu; Xinmin Wang; Chang Liu; Xiaomeng Wang; Zhenyue Dong; Jinghui Niu; Fei Wang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-09-20       Impact factor: 4.342

Review 2.  Results of medial patellofemoral ligament reconstruction compared with trochleoplasty plus individual extensor apparatus balancing in patellar instability caused by severe trochlear dysplasia: a systematic review and meta-analysis.

Authors:  Peter Balcarek; Stephan Rehn; Nick R Howells; Jonathan D Eldridge; Keisuke Kita; David Dejour; Manfred Nelitz; Ingo J Banke; Delphine Lambrecht; Markus Harden; Tim Friede
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-10-27       Impact factor: 4.342

Review 3.  Trochleoplasty provides good clinical outcomes and an acceptable complication profile in both short and long-term follow-up.

Authors:  Laurie A Hiemstra; Devin Peterson; Michael Youssef; John Soliman; Laura Banfield; Olufemi R Ayeni
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-11-29       Impact factor: 4.342

4.  Recurrent patellar dislocations: trochleoplasty improves the results of medial patellofemoral ligament surgery only in severe trochlear dysplasia.

Authors:  Stefano Zaffagnini; Davide Previtali; Simone Tamborini; Gherardo Pagliazzi; Giuseppe Filardo; Christian Candrian
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-03-22       Impact factor: 4.342

5.  Assessment of demographic and pathoanatomic risk factors in recurrent patellofemoral instability.

Authors:  Laurie Anne Hiemstra; Sarah Kerslake; Mark Lafave
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-10-07       Impact factor: 4.342

Review 6.  Good patient satisfaction with low complications rate after trochleoplasty in patellofemoral instability.

Authors:  Paolo Ferrua; Riccardo Compagnoni; Filippo Calanna; Pietro Simone Randelli; David Dejour
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-03-30       Impact factor: 4.114

Review 7.  Early osteoarthritis of the patellofemoral joint.

Authors:  Elizabeth A Arendt; Massimo Berruto; Giuseppe Filardo; Mario Ronga; Stefano Zaffagnini; Jack Farr; Paolo Ferrua; Alberto Grassi; Vincenzo Condello
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-04-27       Impact factor: 4.342

Review 8.  Recent developments in evaluation and treatment of lateral patellar instability.

Authors:  Alexander Zimmerer; Christian Sobau; Peter Balcarek
Journal:  J Exp Orthop       Date:  2018-01-10

9.  Outcomes After Deepening Trochleoplasty and Concomitant Realignment in Patients With Severe Trochlear Dysplasia With Chronic Patellofemoral Pain: Results at 2-Year Follow-up.

Authors:  Felix Zimmermann; Danko Dan Milinkovic; Peter Balcarek
Journal:  Orthop J Sports Med       Date:  2021-06-07

10.  Current Concepts in the Management of Patellar Instability.

Authors:  Michael S Laidlaw; David R Diduch
Journal:  Indian J Orthop       Date:  2017 Sep-Oct       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.